Is Grace Therapeutics, Inc. (GRCE) a Buy, Sell, or Hold?
NASDAQ : GRCE
Grace Therapeutics, Inc.
$2.43 USD
$0 (0.0%)
- Volume
- 94.29K
- Average Volume
- 520.58K
- Market Capitalization
- $39.55M
- P/E Ratio
- -4.37
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $5.18
- Year Low
- $1.79
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.10
Company Overview
NASDAQ
Prashant Kohli
Biotechnology
Healthcare
GRCE
5
US
USD
Liquidity Metrics
0.00
8.10
8.10
7.91
0.00
Sales & Valuation
-$
0.00
0.63
-4.45
-0.54
Profitability
-$0.47
-$7.79M
0.00%
0.00%
-14.15%
-13.54%
P/E Metrics
-4.37
-0.14
-0.14
Analyst Price Target & Rating
$4.00
$4.00
$4.00
2/5
2 Analysts
-39.25%
Financial Health Scores
7.09
1/9
$15.23M
$66.65M
$2.76M
-$12.99M
Key Metrics (TTM)
$22.73M
0.00
-1.75
8.10
-14.15%
-16.94%
-22.40%
-22.36%
-64058 days
Company Executives
| Name | Title |
|---|---|
| Carrie D'Andrea | Consultant |
| Amresh Kumar | Vice President of Program Management |
| Robert J. DelAversano | Vice President of Finance and Principal Financial & Accounting Officer |
| R. Loch MacDonald | Member of Scientific Advisory Board & Chief Medical Officer |
| Prashant Kohli | Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Grace Therapeutics, Inc. (NASDAQ:GRCE) Stock
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey. ...
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
2026-06-18 08:00:00
Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Resubmission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the fiscal year ended March 31, 2026.
2026-06-11 12:00:00
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or "the Company") (NASDAQ: GRCE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2026-06-08 13:00:00
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PR Newswire
2026-06-08 12:51:00
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or "the Company") (NASDAQ: GRCE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.
2026-06-03 15:54:00
ATLANTA, June 03, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Grace Therapeutics, Inc. (“Grace Therapeutics” or the “Company”) (NASDAQ: GRCE) complied with federal securities laws. On April 23, 2026, Grace Therapeutics announced the FDA issued a Complete Response Letter (“CRL”) for the Company's New Drug Application for GTx-104 revealing that the CRL referenced certain items “related to leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at our contract manufacturing organization.” The price of the Company's stock dropped following this news.
Grace Therapeutics: Assessing The Path Forward For GTx-104
2026-06-01 05:39:39
Grace Therapeutics is rated a Speculative Buy with a $4 price target, implying 57% upside after a sharp drop from a CMC-only FDA CRL. The FDA's concerns for GTx-104 are limited to fixable chemistry, manufacturing, and controls issues, with no efficacy or safety objections raised. A scenario-weighted DCF model assigns a 75% probability of approval, forecasting $100M peak risk-adjusted U.S. sales and highlighting a favorable risk/reward profile.
2026-05-27 11:33:00
LOS ANGELES--(BUSINESS WIRE)---- $GRCE--GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
2026-05-21 15:45:00
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or the "Company") (NASDAQ: GRCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Frequently Asked Questions
-
What is the current Grace Therapeutics, Inc. (GRCE) stock price?
-
Grace Therapeutics, Inc.(NASDAQ:GRCE) stock price is $2.43 in the last trading session. During the trading session, GRCE stock reached the peak price of $5.18 while $1.79 was the lowest point it dropped to. The percentage change in GRCE stock occurred in the recent session was 0.0% while the dollar amount for the price change in GRCE stock was $0.
-
GRCE's industry and sector of operation?
-
The NASDAQ listed GRCE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GRCE?
-
Carrie D'Andrea | Consultant
Amresh Kumar | Vice President of Program Management
Robert J. DelAversano | Vice President of Finance and Principal Financial & Accounting Officer
R. Loch MacDonald | Member of Scientific Advisory Board & Chief Medical Officer
Prashant Kohli | Chief Executive Officer & Director -
How many employees does GRCE have?
-
Number of GRCE employees currently stands at 5. GRCE operates from 103 Carnegie Center, Princeton, NJ 08540, US.
-
Link for GRCE official website?
-
Official Website of GRCE is: https://www.gracetx.com
-
How do I contact GRCE?
-
GRCE could be contacted at phone #818 839 4378 and can also be accessed through its website. GRCE operates from 103 Carnegie Center, Princeton, NJ 08540, US.
-
How many shares of GRCE are traded daily?
-
The average number of GRCE shares traded daily for last 3 months was 520.58K.
-
What is the market cap of GRCE currently?
-
The market value of GRCE currently stands at $39.55M with its latest stock price at $2.43